Thursday, July 26, 2007

Foresight Is 20/20

Adults choose eye-glasses based mostly on fit and style. But kids' glasses have to withstand the abuses of tree climbing, the playground and boisterous games of tag. For kids younger than 10, David Coats, an ophthalmologist at Houston's Texas Children's Hospital, recommends frames made of plastic, because they're "more likely to withstand a blunt force." Choose clear, impact-resistant lenses made of Trivex ($70 to $150) or polycarbonate ($50 to $100), which also have the bonus of providing 100 percent UVA and UVB protection. Stuart Danker, a pediatric ophthalmologist from Baltimore, also recommends photochromic lenses that darken in the sun and clear up in the shade ($65 to $90;

Pay attention to fit. Anything too big or too heavy can slide down and leave the child looking through the wrong part of the lens. Kids' heads are shaped differently from adults', and a good optician will make sure the glasses fit at three crucial points: the widest part of the face (it should match the width of the glasses), along the nose (a child's nose bridge is flatter than an adult's, and uneven weight distribution can affect nose development) and behind the ears (the frames should point straight back and wrap gently around the ear without pressing into the head). Now they can focus on fun.

By Charlene Dy

Best Hospitals

Legend for chart:

A: Rank
B: Region
C: Hospital
D: Reputation (%)


1 South
Bascom Palmer Eye Institute at the University of Miami 72.2

2 South
Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore 65.0

3 Northeast
8 Wills Eye Hospital, Philadelphia 56.5

4 Northeast
Massachusetts Eye and Ear Infirmary, Boston 31.4

5 West
Jules Stein Eye Institute, UCLA Medical Center, Los Angeles 30.2

6 Midwest
University of Iowa Hospitals and Clinics, Iowa City 18.2

7 South
Duke University Medical Center, Durham, N.C. 16.2

8 West
Doheny Eye Institute, USC University Hospital, Los Angeles 15.0

9 West
University of California, San Francisco Medical Center 7.6

10 Midwest
Barnes-Jewish Hospital/Washington University, St. Louis 7.0

11 South
Emory University Hospital, Atlanta 6.9

12 Midwest
Cleveland Clinic 6.4

13 Northeast
New York Eye and Ear Infirmary 6.2

14 Northeast
New York-Presbyterian Univ. Hosp. of Columbia and Cornell 5.9

15 Midwest
Mayo Clinic, Rochester, Minn. 5.1

16 Midwest
University of Michigan Hospitals and Health Centers, Ann Arbor 4.2

17 South
Cullen Eye Institute, Methodist Hospital, Houston 3.4

U.S. News & World Report, L.P.

Friday, July 13, 2007

Examine the Top 20 Companies in Late and Early Stage of Glaucoma Projects inside

Dublin - Research and Markets has announced the addition of Ophthalmology and Optometry - Glaucoma Drug Pipeline Report to their offering

"Ophthalmology and Optometry - Glaucoma Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of glaucoma drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

* Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
* Keep track of your competitors and partners by better understanding their product pipeline.
* Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
* Maintain a critical competitive advantage.

Content Outline:


Glaucoma Pipeline Overview

* -% of Projects (By Phase of Development)
* -No. of Projects by Phase of Development
* -Marketed Products Vs. Pipeline Products

Company Overview - Pipeline Projects

* -Company Overview - Pipeline Projects
* -Legend
* -Top 20 companies in late stage Glaucoma Projects
* -Top 20 companies in early stage Glaucoma Projects

Full Pipeline View

* -Pre Clinical Pipeline View
* -Phase I Pipeline View
* -Phase II Pipeline View
* -Phase III Pipeline View
* -Pending Approval Pipeline View

Saturday, June 30, 2007

Cat's Eye Implants May Help Humans See

In "Star Trek: The Next Generation," Geordi La Forge is a blind character who can see through the assistance of special implants. While the Star Trek character "lives" in the 24th century, people existing in the 21st century may not have to wait that long for this illuminating technology. Kristina Narfstrom, a University of Missouri, Columbia, veterinary ophthalmologist, has been working with a microchip implant to help blind animals "see." She indicates that the preliminary results are promising.

"About one in 3,500 people worldwide is affected with a hereditary disease, retinitis pigmentosa, that causes the death of retinal cells and, eventually, blindness.

"Our current study is aimed at determining safety issues in regard to the implants and to further develop surgical techniques," Narfstrom explains. "We also are examining the protection the implants might provide to the retinal cells that are dying due to disease progression with the hope that natural sight can be maintained much longer than would be possible in an untreated patient."

Narfstrom is involved primarily with Abyssinian and Persian cats that are affected with hereditary retinal blinding disease. The cat's eye is a good model to use for this type of research because it is very similar to a human eye in size and construction, so surgeons can utilize the same techniques and equipment. Cats also share many of the same eye diseases with humans. The Abyssinian cats that Narfstrom is working with typically start to lose their sight when they are around one or two years old and are completely blind by age four.

During surgery, Narfstrom makes two small cuts in the sclera, the outer wall of the eyeball. After removing the vitreous, which is the gelatinous fluid inside the back part of the eyeball, Narfstrom creates a small blister in the retina and a tiny opening, large enough for the microchip, which is just two millimeters in diameter and 23 micrometers (one-millionth of a meter) thick. The chip includes several thousand microphotodiodes that react to light and produce small electrical impulses in parts of the retina.

"We are really excited about the potential uses for this technology and the potential to create improved vision in some of the millions of people affected worldwide with retinal blindness," Narfstrom relates. "This technology also may be beneficial for pets that have similar diseases because this technology can benefit both animals and humans."

Tuesday, June 26, 2007

Myth Of The Month

No matter how many times Mom warned you about this, it's simply not true, says Marguerite McDonald, M.D., a clinical professor of ophthalmology at Tulane University Health Sciences Center. "Reading in poor lighting will not physically change the eye in any way," she says. "The reason for this misconception is that bright light actually enhances your ability to read because it constricts the pupil, making it easier to focus and see clearly." Younger women may read in dim light for hours on end without any serious consequences, says McDonald. But once you hit your early 40s, this habit may have other effects, such as short-term tension headaches and tired eyes. The reason: "The eye lens becomes more opaque and less flexible as you get older, which makes it difficult to see things at close range to begin with, let alone in poor lighting," she says. "Eventually we'll all need a bright lamp in order to curl up with a good book."

Shape, Jun2007

Thursday, June 21, 2007

West Virginia University remembers founder of Eye Institute

By Eric Bowen

Jun. 19--Ophthalmologist Robert Trotter had a promising career in ophthalmic research at Harvard. But when he found out in the early 1960s that WVU was building a new medical school without an ophthalmology department, he decided to make it his work to ensure the school would include a department for eye specialists.

Trotter uprooted his family and moved back to Morgantown. For two years, he worked part-time in his brother's eye practice while he filed for grants and lobbied for money to build an ophthalmology department without the university's support.

In 1961, when he finally got a government grant, he founded the only department of ophthalmology in the state. It has grown into what is now the WVU Eye Institute.

Trotter died last year, and WVU remembered him Monday with a memorial service at the institute he worked so hard to build. He was recognized as a Distinguished Mountaineer through a proclamation from Gov. Joe Manchin.

"We're so happy to have this kind of institution," said Lionel Chisholm, vice chair of the WVU department of ophthalmology. "It all started with the commitment of Dr. Trotter. I think he deserves a tremendous amount of credit."

Trotter was a 1936 graduate of WVU and went on for medical training at Temple University, then Harvard to study ophthalmology. After founding the ophthalmology department, he served as chair for 20 years, until 1981, training dozens of doctors in ophthalmology.

When he left WVU, Trotter worked in private practice before retiring in 1988.

Trotter's wife, Jodie, said that founding the WVU ophthalmology department was a tremendous accomplishment for her late husband. He went through lean times as a clinician for two years before he received the money to build the department.

"It had to be the highest point of his life," she said. "It was that important to him."

Trotter was dedicated to WVU students, Jodie Trotter said. He was rough on his students, but they learned a lot from him.

"I think there were some that might have called him colorful names, but when it was all over, they knew it was for the best," she said.

Robert Trotter had a vision for what could be achieved at WVU when he came back to the state, said Fred Butcher, vice president for health sciences. Though WVU was just beginning to build a prominent medical school in West Virginia, he could see a future for the university.

He also wanted to care for the people of West Virginia, Butcher said. He came back home to lend his skills to the next generation of ophthalmologists.

"I think [Trotter] had instincts about what was going to happen here," Butcher said. "Things were coming up out of a cow pasture on top of a mountain. Now look what's here today."

Wednesday, March 07, 2007

Years of refinement have made laser eye surgery better than ever

When Cindy Duong decided to pitch her contact lenses and have surgery last summer to correct her nearsightedness, she assumed she'd get LASIK. The procedure, in which a tiny flap is cut across the top of the eye's clear, dome-shaped cornea and folded back so a laser can reshape the tissue underneath, is easily the most common type of laser eye surgery, making up 87 percent of all procedures last year. But Duong's doctor said that the cornea in her left eye was too thin to both cut the flap and contour her cornea as LASIK (short for laser-assisted in situ keratomileusis) surgery requires. Instead, her doctor suggested she consider a procedure she'd never heard of called photorefractive keratectomy.

The PRK procedure doesn't entail a flap. Instead, the surgeon removes the very top layer of cells from the cornea, often by scraping them away after loosening them with alcohol, and then uses a laser directly on the exposed surface to shape it. Although the Food and Drug Administration approved PRK in 1995, a few years earlier than LASIK, the latter quickly surpassed PRK in popularity. That's because patients who had LASIK usually experienced clearer vision right off the bat and felt little pain or scratchiness in their eyes post-surgery. With PRK, the eyes generally take several days to heal comfortably, and vision remains blurry for the first few days or weeks.

Duong had PRK on her left eye and LASIK on her right. As expected, she noticed an immediate improvement in the vision in her right eye and felt no discomfort. Meanwhile, her left eye was irritated, and her vision was blurry for about a week. But then a funny thing happened. As the weeks passed, she noticed that her left eye caught up with and then surpassed the eyesight in her right eye. Her left-eye vision was slightly clearer, and she had fewer problems seeing at night. "Now, my PRK eye is much better than my LASIK eye," says the 26-year-old chemist from Chicago. "At night, there's definitely a blurriness in my right eye more than my left."

Duong isn't the only fan of PRK. Although LASIK remains the laser eye surgery of choice, in the past few years, more eye surgeons have been performing PRK. In some cases, they are turning away from LASIK entirely, say experts. Between 2005 and 2006, the percentage of all laser eye surgeries that were performed using PRK and other "surface ablation" techniques-in which tissue is ablated or removed from the surface of the eye rather than from the inside as it is with LASIK-rose from 8 percent to 13 percent, according to Market Scope, an ophthalmic research company. Meanwhile, the actual number of laser surgeries declined slightly during that time, from 1.41 million to 1.38 million. "Surgeons today are doing a higher percentage of PRK than in the past, and their mix is changing," says Dave Harmon, president of Market Scope.

Two other surface-ablation techniques, LASEK and Epi-LASIK, are essentially newer versions of PRK. Instead of removing the very top layer or "skin" of the eyeball, they push it to one side and then replace it following laser surgery on the surface of the cornea. Research is inconclusive, but many experts say these newer techniques don't actually reduce the discomfort caused by the surface ablation.

To understand how laser eye surgery works, it helps to know how nearsightedness and farsightedness typically occur and how the surgery corrects them. In someone with normal vision, light rays of an image pass through the cornea and the lens behind it and focus directly on the retina, producing a clear image. This nerve-sensitive tissue at the back of the eye converts the image into electrical impulses that travel along the optic nerve to the brain. If someone's eyeball is too long, however, the light rays focus in front of the retina and, if too short, on a point behind it. The surgeon can't change the actual shape of a person's eyeball. However, using a computer-controlled ultraviolet beam of light called an excimer laser, he or she can reshape the cornea, the eye's principal focusing mechanism, to improve visual acuity. (Laser eye surgery can also correct astigmatism, a blurriness that typically occurs when the surface of the cornea is uneven.)

Fool the eye. Refractive surgeons, who generally correct people's vision by changing how light rays "refract," or bend in the eye, discovered that by working inside the eye, as they do with LASIK, they could fool it into not recognizing that it had been wounded by the laser. After surgery, the eye didn't feel painful, since pain is a response to wound healing. And because the eye's surface hadn't been interfered with, vision recovery was immediate. Similarly, LASIK sidestepped a problem that plagued early PRK procedures: A patient's vision was sometimes clouded by a whitish haze caused by scarlike tissue that developed after the surgery. "You've given the eye a loud message that there's been an injury, and the eye will respond with healing," says Richard Foulkes, an adjunct professor of ophthalmology at the University of Illinois, who performed the surgery on Duong. "Too vigorous healing would cause hazing."

Thanks to an antibiotic eyedrop called mitomycin C, the hazing problem has been almost eliminated in the past five years and with it one of the major downsides to PRK. And the use of contact lenses to act as bandages to protect the eyes during the first several days following surgery makes recovery from PRK less painful. At the same time, surgeons have discovered that LASIK isn't necessarily the miracle cure for bad eyesight that it originally appeared to be. For one thing, although a patient's vision is initially better with LASIK, as the weeks and months pass, studies indicate that people who've had PRK may achieve a slight edge in improved eyesight. Dry-eye problems, the No. 1 complication of laser eye surgery, also tend to occur more frequently with LASIK since the surgery cuts into the cornea and severs some of the corneal nerves that stimulate tears.

Finally, there's the flap itself. Most flaps are cut with a mechanical blade called a microkeratome. If the flap is too thick or too thin or cuts an uneven plane, it can affect the outcome of the surgery. The flap could wrinkle or not reseal itself properly. And in some patients, cutting a flap carries a slight risk of structurally weakening the cornea itself, which can lead to a very serious condition called ectasia, in which the cornea bulges out. Although many early laser eye surgery problems have been resolved in the more than 10 years that the procedure has been performed, those that remain are almost always related to the flap, says Marguerite McDonald, a clinical professor of ophthalmology at Tulane University Health Sciences Center. Word to the wise: "You can't have problems with the flap if you don't have one," she says.

About 3 percent of people who have laser eye surgery continue to suffer from complications six months after the procedure. Now, new technology is making laser eye surgery more accurate and safer. Instead of a mechanical knife, more surgeons are starting to use a laser called the IntraLase to cut the flap for LASIK surgery. With the IntraLase, surgeons can much more precisely control the depth and diameter of the flap. "IntraLase is the closest we've come to getting accuracy that matches surface ablation," says Foulkes.

Precise map. In the past, surgeons simply programmed a person's prescription into the laser to tell it how to trim the cornea. Now, more refractive surgeons are using "wavefront" technology for both LASIK and PRK that creates a more precise map of the unique optical landscape of a patient's eyes. With wavefront, the laser can be set to deal with "higher-order aberrations"-there are about 20 of them-that are responsible for things like glaring and starbursts, says Jim Salz, a clinical professor of ophthalmology at the University of Southern California. "We have a better chance of making your vision 20/20," Salz says, "and fewer optical problems."

Laser eye surgery isn't typically covered by insurance, and it's not cheap, especially using the new technology. At Salz's Los Angeles practice, LASIK with wavefront and IntraLase costs $2,800 per eye. PRK is a bit less expensive, at $2,300 per eye without wavefront. Prices may be lower in different parts of the country, and high-volume centers may charge significantly less than $2,000 an eye. But price and whiz-bang technology aren't the only elements to consider in the decision-making process. "No amount of technology can make up for an inferior surgeon," says Glenn Hagele, executive director of the Council for Refractive Surgery Quality Assurance, a consumer information group. On its website (, the council lists eye surgeons it certifies who meet its standards for postoperative visual acuity and patient satisfaction, among other things. In addition, the group's list of "50 tough questions for your LASIK doctor" tells potential patients what to ask any doctor they're considering for LASIK or other refractive eye surgery.

Not everyone is a suitable candidate for laser eye surgery. People with very high corrections may not get satisfactory results, for example. But even with a good surgeon working on an ideal candidate, the results can be subpar. "There's no smoking gun," says David Hartzok, executive director of the Vision Surgery Rehab Network in Rockford, Ill., which offers support and assistance to people who've had complications following eye surgery. "More than half the time, we simply don't know why some patients have problems."

After laser eye surgery, about 90 percent of patients achieve at least 20/40 vision, the legal minimum in many states for driving without glasses, according to the American Academy of Ophthalmology. Up to 10 percent of patients need enhancement surgery to fine-tune the results of the original procedure. But being able to read an eye chart isn't the only measure of a successful surgery, and it's in this area that many patients continue to have problems.

Andrew Jankovich had the Cadillac of LASIK eye procedures. His Cincinnati surgeon used the IntraLase laser to cut the flap and wavefront technology to guide the laser that reshaped his corneas. Following the surgery, his vision was 20/15, and his doctor said everything looked fine. But almost immediately, he noticed that his left eye was scratchy and irritated. Instead of going away, the problem worsened, and he now has severe dry eye. It's been a year now, and he says he constantly feels as if there's a hair in his eye or a raw spot there. Special eyedrops make it slightly better, but it never goes away. If he could make the choice again, Jankovich says, "I'd wear 3-inch-thick glasses instead."

For many people, ditching their glasses is a big part of the appeal of laser eye surgery. But before you pony up thousands of dollars, make sure you understand the potential risks and limitations. Only then can you make a clear-eyed choice.


In LASIK eye surgery, the surgeon cuts a small flap across the surface of the cornea-- the clear window on the front of the eye that transmits and focuses light. Next, the flap is folded back, and the surgeon reshapes the cornea using a laser that vaporizes the tissue. With photorefractive keratectomy, the procedure is similar except that the surgeon doesnt create a flap before using the laser to trim the cornea.

The problem

Nearsightedness and farsightedness are generally caused by differences in eyeball shape. LASIK and PRK correct for this by recontouring the cornea.

Normal eye: Light rays focus directly on the retina.

Nearsighted: Light focuses in front of the retina when the eye is too long.

Farsighted: Light focuses on a point behind the retina when the eye is too short.

By Michelle Andrews (

Saturday, February 17, 2007

Inspire Announces Licensing Agreement

Inspire (NASDAQ:ISPH) is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite(TM) and DuraSite are trademarks owned by InSite Vision Inc. For more information, visit

At the time of writing shares are up 4% to $7.67 with over 324,000 in volume. This momentum comes as Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the signing of an exclusive licensing agreement with InSite Vision Incorporated (AMEX: ISV) for the U.S. and Canadian commercialization of AzaSite(TM) (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit

Under the terms of the agreement, Inspire has acquired from InSite Vision exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite , InSite Vision's patented drug-delivery vehicle.

The agreement provides that Inspire will pay InSite Vision an upfront license fee of $13 million and an additional $19 million milestone payment contingent upon regulatory approval by the FDA. Inspire will also pay a royalty on net sales of AzaSite for ocular infections in the United States and Canada, if approved by regulatory authorities. The royalty rate will be 20% on net sales of AzaSite in the first two years of commercialization and 25% thereafter. Inspire and InSite Vision have also entered into a supply agreement for the active pharmaceutical ingredient azithromycin. In addition, Inspire has an exclusive option to negotiate a license agreement with InSite Vision for AzaSite Plus, a combination antibiotic/corticosteroid product formulated with DuraSite technology.

Christy L. Shaffer, Ph.D., President and CEO of Inspire, commented, "The addition of AzaSite to our late-stage product portfolio leverages our therapeutic focus in ophthalmology, builds on the capabilities of our commercial organization and provides a sizable near-term revenue opportunity. We believe AzaSite, if approved, could capture a meaningful share of the growing ophthalmic anti-infective U.S. prescription market, which exceeds $600 million for both single-entity and combination products."

"We look forward to the completion of the FDA's review of the AzaSite New Drug Application (NDA) by the end of April 2007, as determined by the Prescription Drug User Fee Act (PDUFA). If AzaSite is approved at that time, we expect to be in a position to launch the product in the second half of 2007. Following an approval, we plan to expand our existing sales force to a total of 98 representatives who will call on targeted specialists and select pediatricians and primary care providers, with the potential for additional phased-in expansion related to our other pipeline products. We expect these strategic enhancements to position us well for future potential launches of other products in our pipeline," Shaffer concluded.

Terrence P. O'Brien, M.D., Professor of Ophthalmology and Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology, Bascom Palmer Eye Institute of the University of Miami, commented, "AzaSite represents an exciting new potential treatment option for external ocular infections, including bacterial conjunctivitis. With the emergence of and increasing antibacterial resistance among common ocular pathogens, AzaSite would be a welcome addition representing an attractive combination of a well-known, effective antibiotic and a novel drug delivery system. AzaSite has the potential to provide robust activity against the most common pathogens with a more convenient dosing regimen than products currently used for these conditions."

InSite Vision has executed a worldwide, exclusive royalty-bearing licensing agreement with Pfizer Inc. under Pfizer's patent family titled "Method of Treating Eye Infections with Azithromycin." Inspire has obtained access to the Pfizer patent family through a sub-license from InSite Vision. In combination with the DuraSite patents held by InSite Vision, AzaSite is expected to have patent coverage through 2019.

Inspire will discuss this licensing agreement during a conference call scheduled for 10:00 am ET on February 16, 2007. To access the conference call, U.S. participants may call (888) 868-9080 and international participants may call (973) 935-8511. The conference ID number is 8460144. A live webcast and replay of the call will be available on Inspire's website at A telephone replay of the conference call will be available until March 2, 2007. To access this replay, U.S. participants may call (877) 519-4471 and international participants may call (973) 341-3080. The conference ID number is 8460144.

About AzaSite(TM)

AzaSite is azithromycin 1.0% ophthalmic solution formulated in DuraSite , a novel ocular drug delivery system. Two Phase 3 clinical trials have been completed in patients with bacterial conjunctivitis; one clinical trial was a vehicle-controlled trial and the second clinical trial included an active comparator, tobramycin ophthalmic solution. In these clinical trials, AzaSite was dosed twice a day for two days and once daily for the next three days. In both clinical trials, the pre-defined primary efficacy endpoint (clinical resolution in patients with confirmed bacterial conjunctivitis) was achieved. Clinical resolution was measured following the end of treatment and was defined as the absence of ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection. Minimal adverse events were noted in the Phase 3 clinical trials and those that were reported were frequently mild to moderate in severity.

About Azithromycin

Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and has been available under the trade name Zithromax by Pfizer Inc. since 1992. Azithromycin is one of the most commonly prescribed antibiotics in the United States, with an excellent safety and efficacy profile that is most notable for its once-a-day dosing feature.

About Bacterial Conjunctivitis

Bacterial conjunctivitis is a common ocular surface microbial infection characterized by inflammation of the conjunctivae, which are the mucous membranes covering the whites of the eyes and the inner side of the eyelids. The infection, which is common in children, is contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness. The most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species.

This article is available for viewing in the Featured Articles Section on our website. To view this article and comparables join us at for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed.

The Financial Information and Financial Content provided by is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.

All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

Source: M2PressWIRE, Feb 16, 2007